Legal, Ethical & Social Analysis of Preclinical Biomarker Tests in Alzheimer’s Disease

  • Study Director: Jalayne Arias, JD, MA
  • Sponsor: Alzheimer’s Association
  • Official Study Title: Legal, Ethical & Social Analysis of Preclinical Biomarker Tests in Alzheimer’s Disease
  • Conditions Studied: Alzheimer’s disease (AD)

Purpose of the Study

The purpose of this study is to determine the potential legal, ethical and social consequences of documenting Alzheimer’s disease (AD) biomarkers in asymptomatic patients’ medical records. This includes determining professional stakeholders’ perspectives on clinicians’ obligations when documenting and managing positive preclinical biomarker test results.

Study Details

This study involves three cohorts:

  1. Human resource managers,
  2. Physicians and
  3. Long-term care insurance underwriters.

We are interested in how these cohorts view and would potentially use medical test information in professional decision-making. The study is currently recruiting human resource managers and professionals and insurance underwriters.

What to Expect

Participation includes a single interview conducted via telephone. The interview will last between 30 to 60 minutes and will be recorded, transcribed and analyzed. There are no costs for participating in this study.

Contact Information

If you are interested in participating in this study or have any questions, please contact the study coordinator Krystal Karunungan at [email protected] or the principal investigator, Jalayne Arias, at [email protected] or 415.353.3597.